Form 13-F position report

G1 THERAPEUTICS INC

Reported by GEODE CAPITAL MANAGEMENT LLC

GTHX CUSIP 3621LQ109 Manager CIK 0001214717

Reported 440,633 shares, up 8,981 (2.1%) from the prior quarter.

Reported value -40.9%; share count 2.1% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q3 2023
Shares 440,633 Quarter-end amount reported
Reported value $634,678 Fair value at quarter end
Consecutive quarters held 26 Through Q3 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 8630000
2021-12-31 7303000
2022-03-31 5077000
2022-06-30 1688000
2022-09-30 4337000
2022-12-31 1925000
2023-03-31 1174895
2023-06-30 1074813
2023-09-30 634678
2023-12-31 1405683
2024-03-31 2185572
2024-06-30 2462179
2024-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

13 quarters
Quarterly reported position history for G1 THERAPEUTICS INC held by GEODE CAPITAL MANAGEMENT LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2024 Reduced 0 -1,079,645 (-100.0%) 0 $0 2024-11-12
Q2 2024 Added 1,079,645 +573,840 (113.5%) < 0.01% $2,462,179 2024-08-09
Q1 2024 Added 505,805 +45,030 (9.8%) < 0.01% $2,185,572 2024-05-13
Q4 2023 Added 460,775 +20,142 (4.6%) < 0.01% $1,405,683 2024-02-13
Q3 2023 Added 440,633 +8,981 (2.1%) < 0.01% $634,678 2023-11-13
Q2 2023 Reduced 431,652 -6,742 (-1.5%) < 0.01% $1,074,813 2023-08-11
Q1 2023 Added 438,394 +83,855 (23.7%) < 0.01% $1,174,895 2023-05-15
Q4 2022 Added 354,539 +7,284 (2.1%) < 0.01% $1,925,000 2023-02-13
Q3 2022 Added 347,255 +5,360 (1.6%) < 0.01% $4,337,000 2022-11-14
Q2 2022 Reduced 341,895 -326,245 (-48.8%) < 0.01% $1,688,000 2022-08-12
Q1 2022 Reduced 668,140 -47,233 (-6.6%) < 0.01% $5,077,000 2022-05-13
Q4 2021 Added 715,373 +72,270 (11.2%) < 0.01% $7,303,000 2022-02-11
Q3 2021 Added 643,103 +32,779 (5.4%) < 0.01% $8,630,000 2021-11-12
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

89 managers reported G1 THERAPEUTICS INC for Q3 2023.

Managers reporting G1 THERAPEUTICS INC in Q3 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
VANGUARD GROUP INC Unchanged 1,950,068 0 < 0.01% $2,808,098 26 qtrs
BlackRock Inc Reduced 1,120,307 -65,338 < 0.01% $1,613,240 26 qtrs
MILLENNIUM MANAGEMENT LLC Added 1,048,995 +440,930 < 0.01% $1,510,553 8 qtrs
RAYMOND JAMES & ASSOCIATES Added 925,776 +133,662 < 0.01% $1,333,117 16 qtrs
JACOBS LEVY EQUITY MANAGEMENT INC Added 573,256 +80,480 < 0.01% $825,489 6 qtrs
MARSHALL WACE LLP Added 516,728 +461,128 < 0.01% $744,089 7 qtrs
D E Shaw & Co Inc Reduced 505,082 -111,421 < 0.01% $727,318 6 qtrs
RENAISSANCE TECHNOLOGIES LLC Reduced 474,080 -97,711 < 0.01% $683,000 6 qtrs
GEODE CAPITAL MANAGEMENT LLC This report Added 440,633 +8,981 < 0.01% $634,678 26 qtrs
XTX Topco Ltd Added 296,601 +186,753 0.07% $427,105 6 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2023
Filed
November 13, 2023
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
440,633
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.